Bicara Therapeutics
BCAX
114 hedge funds and large institutions have $789M invested in Bicara Therapeutics in 2025 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 41 increasing their positions, 26 reducing their positions, and 17 closing their positions.
66% more capital invested
Capital invested by funds: $475M → $789M (+$314M)
58% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 26
47% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 17
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
8% more funds holding
Funds holding: 106 → 114 (+8)
1.82% less ownership
Funds ownership: 93.82% → 92% (-1.8%)
99% less call options, than puts
Call options by funds: $3K | Put options by funds: $350K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$5.2M |
| 2 |
ClearBridge Investments
New York
|
+$3.63M |
| 3 |
Millennium Management
New York
|
+$3.07M |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$2.81M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$2.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMV
Foresite Capital Management VI
Larkspur,
California
|
-$8.82M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.42M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$3.74M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$3.72M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
-$2.82M |
BCAX Hedge Fund Activity: Q3 2025 in Review
114 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Bicara Therapeutics (BCAX) for Q3 2025, worth a combined $789M — up 66% from $475M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new BCAX positions and 17 closed out — a net gain of 8 holders — while 41 added to existing stakes and 26 trimmed.
The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $5.2M. The largest seller was Foresite Capital Management VI, exiting entirely with an estimated $8.82M sold.
- 114 institutional investors held Bicara Therapeutics (BCAX) as of Q3 2025, up from 106 in Q2 2025.
- Funds reported $789M of Bicara Therapeutics stock for Q3 2025, up 66% quarter-over-quarter.
- 25 funds opened new Bicara Therapeutics positions in Q3 2025 and 17 closed out, a net change of +8 holders.
- The largest Bicara Therapeutics buyer in Q3 2025 was T. Rowe Price Investment Management, an estimated $5.2M added.
- The largest Bicara Therapeutics seller in Q3 2025 was Foresite Capital Management VI, an estimated $8.82M sold.
Based on aggregated 13F filings for Q3 2025.